Skye Bioscience (SKYE) Capital Expenditures (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Capital Expenditures of -$18001.0 for Q1 2026, down 385.19% year-over-year from $6312.0 in Q1 2025, and down 185.19% quarter-over-quarter from -$6312.0 in Q4 2025.
Skye Bioscience (SKYE) Capital Expenditures (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Capital Expenditures for 12 consecutive years, with -$18001.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 385.19% year-over-year to -$18001.0; the TTM figure through Mar 2026 stood at -$24313.0 (down 149.89% YoY), while the FY2024 annual figure was $45601.0, up 263.35% from the prior year.
- Capital Expenditures eased to -$18001.0 in Q1 2026 per SKYE's latest filing, from -$6312.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.5 million in Q3 2024 and bottomed at -$1.5 million in Q4 2024.
- Historically, Capital Expenditures has averaged $4872.1 across 5 years, with a median of $2590.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 81732.2% in 2024 and fell as far as 12119.14% in 2024.
- Skye Bioscience's Capital Expenditures stood at -$923830.0 in 2022, then jumped by 101.36% to $12550.0 in 2023, then tumbled by 12119.14% to -$1.5 million in 2024, then jumped by 99.58% to -$6312.0 in 2025, then plunged by 185.19% to -$18001.0 in 2026.
- Business Quant data shows SKYE's Capital Expenditures at -$18001.0 in Q1 2026, -$6312.0 in Q4 2025, and $6312.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | -27,600.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,001.00 |
| Mar 31, 2026 | -18,001.00 |
| Dec 31, 2025 | -6,312.00 |
| Dec 31, 2025 | -6,312.00 |
| Mar 31, 2025 | 6,312.00 |
| Mar 31, 2025 | 6,312.00 |
| Dec 31, 2024 | -1.51 Mn |
| Dec 31, 2024 | -1.51 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 32,463.00 |
| Jun 30, 2024 | 32,463.00 |
| Mar 31, 2024 | 3,181.00 |
| Mar 31, 2024 | 3,181.00 |
| Dec 31, 2023 | 12,550.00 |
| Dec 31, 2023 | 12,550.00 |
| Sep 30, 2023 | -1,860.00 |
| Sep 30, 2023 | -1,860.00 |
| Mar 31, 2023 | 1,860.00 |
| Mar 31, 2023 | 1,860.00 |